click enter text
assum coverag peer perform
take wait approach deal combin
cvs/aet interest take time develop current valuat
wolf ep consensu ep certainli demand
lay report see busi momentum
moder leav stand-alone high next year coupl
broadli limit visibl growth across pharmaci pbm
busi prefer wait color cvss hc deliveri strategi
potenti get construct host webcast today
et go analysi hc servic landscap
deal clearli accret stand-alon origin
estim guid aet transact neutral year
low-to-mid singl digit accret year lay pg
stand-alon certainli debat aet result ahead plan
benefit tax reform aet origin contempl
leav deal accret ep
said unclear grow ebit management
indic fewer rfp opportun pbm busi
continu pressur margin across segment appear like
co ex-aet miss consensu growth
next year model stand-alon net inc declin
pg lay deal accret post-deal earn power
newco assum core net incom low-singl digit go forward
healthcar deliveri strategi take time develop could
power over-promis under-deliv sever deal
notabl caremark management smartli taken measur tone
convey expect develop ramp implement hc
cost contain deliveri strategi investor day expect
includ broad goal point said cvs/aet interest
set core asset allow investor dream dream co
enabl lower cost via integr health benefit pbm pharmaci local
hc deliveri long-term
pt stand-alone pt base ep
target multipl cvs-aet pt base
pf cvs-aet ep target multipl
trade fundament data
upsid target
total debt total cap
float
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
tabl content
import drug trend
growth specialti
strategi dream dream
manag board director
page
take wait see approach point assum coverag peer perform rate
stand-alone ye price repres upsid tuesday close pf cvs-aet year end
pt repres upsid tuesday close brief combin aet highli
like given depart justic approv interest take time develop current valuat
wolf ep consensu ep certainli demand lay report see
busi momentum moder leav stand-alone high next year coupl broadli
limit visibl growth across pharmaci pbm busi prefer wait color
compani healthcar deliveri strategi potenti get construct
addit detail stand-alone -aet pt build-up stand-alone pt
base ep target multipl aet pt base
pf -aet ep target multipl note current target multipl
aet histor rang given concern around pressur margin throughout legaci busi
segment stand-alone also current trade ntm market multipl larg discount
page
ebit ebit midpoint midpoint midpoint midpoint weight rel price-to-earnings specif prem rel valu rel price-to-earnings multipl wr pt builduppt midpoint rel price-to-earnings specif prem rel valu rel price-to-earnings multipl wr
addit thought cvs-aet valuat rel consid primari peer group
see exhibit cvs-aet signific portion earn come slower-growth
busi believ also pressur margin
page
page
invest posit summari upsid risk
deliv right drug right increas import time
expect debat pbm econom continu forese futur clear pbm offer
value-ad servic increas import time given acceler drug trend
growth specialti drug distribut remain opportun
specialti drug fastest grow area therapeut spend allow pbm offer greatest
amount valu ad servic includ administr drug deliveri patient educ clinic management
given deal announc pre-tax reform significantli benefit aetna bottom line aetna
ahead plan see deal accret stand-alon estim vs prior
commentari non-impact year low-to-mid singl digit accret year
ep stand-alone trade discount pt -aet trade
discount pt current multipl rel low compar histor averag
optum dream dream fully-integr vertic healthcar platform
invest concern summari downsid risk
pbm margin pressur unlik abat
unclear ultim market clear margin pbm industri continu believ
pbm margin pressur without take addit risk
retail pharmaci margin pressur
retail pharmaci margin continu pressur much upsid suppli chain manag
improv gener penetr negoti away pass back client
consolid basi stand-alon ebit net incom estim
vs consensu
difficult quantifi impact potenti chang exist feder state law regul
purchas discount rebat arrang pharmaceut manufactur addit
dismiss amazon potenti disruptor pharmaci space
unlik get benefit doubt deliv smooth integr
given integr issu experienc caremark acquisit deliber
conserv give specif guidanc around long-term opportun cvs-aet transact
page
invest posit deliv right drug right increas import time
net pharmaceut drug spend reach accord iqvia importantli
acceler meaning last sever year back greater consumpt high cost specialti
therapi backdrop pbm pharmaci ampl opportun provid valu via typic
lever price negoti formulari control well manag site servic deliveri step therapi
prior author
exhibit project increas prescript drug spend
exhibit specialti drug spend expect account total pharma drug spend
page
specialti drug continu fastest grow expens segment pharmaci care total
specialti spend expect total pharmaceut drug spend countri specialti
spend continu grow diseas like rheumatoid arthriti cancer becom preval drug
compani continu target common condit high cholesterol asthma hepat increas
potenti pool patient unsurprisingli accord pbmi specialti drug benefit report
employ respond list manag specialti drug cost number one prioriti
larg pbm disclos drug trend caremark esrx medimpact prime report overal drug spend
increas less vs inflat commerci plan context
surpris provid medicar advantag plan option appli step therapi physician-
administ part drug plan choic implement step therapi manag part
exhibit pbm report overal drug spend increas less vs inflat commerci plan
expect debat pbm econom continu forese futur clear scale
signific barrier entri provid cushion margin pressur time convers
key industri leader consult well optumrx exampl suggest take script
maxim purchas power competit three larg pbm level pbm
continu take share combin basi organ via acquisit valu scale accru
significantli form purchas power compani indic high retent rate last
sever year cost margin extent
page
commerci drug trend pbm
exhibit pbm market share base script manag
invest posit growth specialti drug distribut remain opportun
mention specialti drug spend continu fastest grow expens segment
pharmaci care believ current structur specialti market allow pbm continu gain share
specialti dispens space two main reason
employ health plan requir use design specialti pharmaci specialti drug lower cost
accord latest pbmi survey employ respond report requir use
design specialti pharmaci arguabl believ pbm provid better rate pbm client
compar stand-alon specialti pharmaci given pbm may take firm-wide view custom
profit therefor abl tap multipl profit pool outsid specialti gener
accept return custom
manufactur often limit specialti distribut network monitor patient adher influenc servic
level aggreg patient data manag suppli etc diplomat state trend toward limit
distribut specialti drug continu expand strong footprint area essenti
believ pbm prescrib influenc better negoti power demand access limit
network compar stand-alon specialti pharmaci
page
exhibit current structur specialti market allow pbm continu gain share
accord slide investor day decemb estim specialti
dispens revenu addit non-dispens specialti revenu remain potenti
revenu opportun specialti dispens revenu estim grown
compound-annual-growth-rate compar overal industri growth support belief pbm better
posit captur share
page
specialti pharmaceut market sharemanufacturerslimit network monitor patient adher influenc servic level aggreg patient data manag suppli etc even open distribut product payer employ health plan limit network reduc cost reason specialti pharmaci own larg pbm maintain largest market share parent organizationmarket sharecv inclus limited-distribut network provid critic sourc revenu growth provid catalyst futur growth -dplo
exhibit estim specialti dispens revenu
exhibit non-dispens specialti revenu remain potenti revenu opportun
believ growth specialti dispens revenu continu sourc profit simpl
hypothet illustr show simpli maintain current market share grow specialti
dispens market could grow compani ebitda annual assum chang
page
exhibit specialti dispens revenu continu sourc profit
invest posit tax reform aetna deal accret initi discuss
-aet transact announc decemb commun deal would
meaning impact earn year one becom low-to-mid-singl digit accret full year vs
consensu estim time given deal announc prior tax reform pass benefit
specif aetna side term increas net incom includ accret guidanc
exhibit cvs/aet deal announc deal expect low-to-mid-singl digit accret full year
base inform provid announc deal without adjust tax reform benefit
well increment expens see accret accret vs consensu
estim time unsurprisingli in-lin compani expect
page
billion specialti growth specialti dispens market share pbm ebitda wr ebitda wr specialti pbm ebitda margin wr total pbm ebitda specialti total compani
time provid expect beyond believ compani would seen mid-singl
digit accret low-teen base assumpt vs pre-tax reform
illustr exhibit
exhibit cvs-aet pro-forma ep deal announc
number move part post deal announc impact deal accret signific
move part includ tax-reform benefit aet ii tax-reform reinvest
aet iii earn project vs prior estim aet iv cost includ
implement cost consid addit benefit cost post announc deal
well aet perform ytd believ deal accret stand-
alon estim note analysi incorpor project corpor synergi
second full year ramp year follow complet transact includ
revenu synergi anyth requir signific new invest
meanwhil deal appear meaning accret vs current consensu estim
consensu estim seem optimist view discuss thought
stand-alon forward estim later section note
page
forma incom statement million deal net incomecv adjust net adjust net adjust net adjust pre-taxdivest interest transact adjust tax transact adjust forma adjust net forma share forma adjust stand-alone ep ensu estimate vs
exhibit consid move part post deal announc get pro forma ep
page
wr forma vs consensu stand-alon stand-alon accret origin forma ep origin tax reform net tax reform net pbm growth adjustmenta discuss earlier slide stand-alon est lower consensu estimate new forma forma ep -post-tax incl implement stand-alon current consensu consensu
exhibit deal appear accret stand-alon estim
manag provid extens detail potenti long-term synergi combin
compani synergi minuteclin hub store like improv valu proposit transact
beyond initi synergi compani project concern around implement
discuss invest risk section expect take care approach
make invest note compani guid specif revenu synergi either believ
uncertainti well reflect current valuat compani stock trade forward
earn signific discount market multipl compani histor rang
stand-alone pt base ep target multipl
aet pt base pf cvs-aet ep target multipl note current
target multipl -aet histor rang given concern around
pressur margin throughout legaci busi segment stand-alone also current trade
ntm market multipl
page
page
ebit ebit midpoint midpoint midpoint midpoint weight rel price-to-earnings specif prem rel valu rel price-to-earnings multipl wr pt builduppt midpoint rel price-to-earnings specif prem rel valu rel price-to-earnings multipl wr
trade well histor rang rel peer multipl expans driven
improv clariti busi fundament could help drive signific price appreci
exhibit histor rel price-to-earnings peer
page
invest posit dream dream fully-integr vertic healthcar platform
first two year cvs-aet transact primarili focus integr two compani
initi cost synergi target second full year rel straightforward outlin
streamlin redund corpor function improv price third parti vendor combin pbm pdp
oper improv enterpris dispens improv patient manag lead reduc spend shift
patient lower cost site care via exist asset minuteclin coram addit would note asid
initi synergi combin cvs-aet also abl produc compet
 invest cvs/aet interest set core asset allow investor dream
dream co enabl lower cost hc deliveri via integr health benefit pbm pharmaci local hc
deliveri long-term
exhibit cvs/aet interest set core asset
well known combin pharmaci medic benefit creat opportun improv afford
improv qualiti close gap care drive addit engag physician patient longer term
deal offer sever interest path creat sharehold valu tackl problem rise faster-
than-infl healthcar cost america
page
 rank retail pharmaci store incl retail clinic script dispens script manag specialti dispens member govern medic comparison healthcarenew pf free estimate revenu estimate bubbl size rel market cap
exhibit quot benefit integr pharmaci medic
would note four focu area could potenti lead creation long-term synergi integr
medic pharma spend chronic care manag minuteclin adopt hub-and-spok
model retail store
page
abl prove integr approach identifi gap care close gap care guid member compliant medic reduc hospit visit coupl effort significantli improv pharmaceut price believ ingeniorx well posit meaning growth specialti pharmaci fastest-grow medic spend categori therapi becom target care becom person pharmaci also typic caus gap health care thewrong drug wrong dosag wrong durat thiscombinationpres opportun close gap effect lower health risk improv qualiti life custom creat valu employ lower medic cost higher product demonstr integr medic pharmaci result increas case manag engag pmpm reduct total medic cost member chronic condit save approach per member per month pharmaci care servic show save patient per year synchron pharmaci andmed engag appli typic employ pharmaci spend save per year top per year save per member pharmaci benefit distinguish featur antm ceo gail boudreauxci ceo david cordaniaet ceo mark bertoliniunh ceo david wichmann
integr medic pharma benefit pbm multipl health plan spoken benefit
integr medic pharmaci spend combin usual lead lower cost due improv patient
manag better util combin data analyt per aet ceo mark bertolini integr
medic pharmaci result increas case manag engag pmpm
reduct total medic cost
chronic manag chronic condit drive signific amount total healthcar spend us
estim cvs-aet attempt reign spend via integr pharmacist
patient care lead better patient manag schedul improv therapi local assess
improv adher focu improv manag largest chronic diseas
diabet
minuteclin popul live within mile minuteclin offer consum
afford visit minuteclin would help reduc health spend given lower cost site care reduc
er visit dream dream scenario minuteclin would offer afford gateway concierg
healthcar consum may also expans servic minuteclin given current
offer servic pcp target addit servic offer may includ lab
servic educ nutrit
page
integr medic pharma pbmminuteclinicchron managementhub modelmultipl health plan spoken benefit integr medic pharmaci lead reduc total spend integr medic pharmaci result increas case manag engag pmpm reduct total medic cost mark bertolini popul live within mile minuteclinicpotenti expans servic minuteclin grow urgent care offer potenti offer includ lab servic educ nutrit hc conciergelow cost site care reduc er visit lower cost consumerimprov local patient managementintegr pharmacist patient care pharmacist-lead interventionsbett patient manag schedul improv therapi local assessmentsimprov adher focu chronic diseas includ diabet high blood pressur high cholesterollook move aggress direct lead aet membership proof point customersgateway healthcar concierg servic test pilot potenti addit servic offer audiolog dialysi dialysi train dispens dme educ infus vision etc servic pcpsite care cost reduct lifestyl manag hub play role social determin healthoption add urgent care capabl appear front mind time
creat healthcar hub beyond retail store core set servic avail broadli
across retail store subset hub store would enhanc servic pilot differ
concept order figur ultim roll hub spoke store includ audiolog dialysi
 dialysi train dispens dme educ infus lab nutrit vision etc ideal hub store
would offer servic tradit pcp also play role lifestyl manag social
determin ultim store would also rel site care cost reduct
page
given locat found throughout countri signific last mile presenc
popul live within mile pharmaci may interest new patient manag cost
util techniqu combin entiti would abl implement via nation footprint health
plan simpli physic retail footprint may stand-alone detriment today amazon
age note may offer uniqu opportun retool reutil combin co
exhibit overlay aet membership deal announc w/ retail store state show
signific overlap
expect take time cvs-aet lay full suit offer detail strategi like
phase roll-out color upon close expect investor day still time
manag test variou model across facil base take time undeni
combin offer uniqu offer unlik healthcar yet see full benefit
combin scale pbm nation pharmaci nation health plan one roof
page
page
invest risk pbm margin pressur unlik abat
well-known among investor pbm industri experienc margin pressur result
competit pressur increas client demand lower price enhanc servic offer higher
servic level importantli client demand increas sophist around transpar rebat
underli drug price discount even drug manufactur administr fee collect pbm like
continu put downward pressur pbm econom exacerb inabl industri
particip investor ascertain reason market clear pbm margin ebitda per script look
like leav sustain earn power difficult determin
exhibit pbm industri experienc margin pressur result competit pressur
convers pbm key industri leader consult suggest pbm profit model shift
commodit transact services-bas model align risk share service-bas model
mitig on-going shift transpar industri unclear ultim market clear
margin pbm industri continu believ pbm margin pressur without take
page
exhibit pbm profit model shift commodit transact services-bas model align risk
addit one area particular concern pick industri particip convers
around potenti neg effect lower pharmaceut price inflat particularli trend moder
gross price awp price increas
page
profit pooltradit pbm modelpbm servicesreb retent manufactur feesbuy/sel spreadmail order distributionnetwork managementprofit poolrisk share service-bas pbm modelpbm servicesshar save arrangementcar coordinationmail order specialti distributiontrend price guaranteereb guarante value-bas contractsour inabl maintain posit trend failur identifi implement new way mitig price pressur could neg impact abil attract retain client sell addit servic could neg impact margin materi advers effect busi result oper esrx formulari manag
concern pbm other drug suppli chain contract custom often via
discount rebat guarante deliv increas discount rebat life contract typic
year pbm higher initi gross price pharma manufactur put annual greater
opportun pbm negoti greater discount rebat still allow inflationari price
flow thru pharma lower gross price increas becom difficult pbm hit discount
rebat target go forward leav signific focu drug price expect januari
exhibit pbm typic take risk contract term normal set month contract begin
normal includ level improv price rebat contract life
page
reimbursementyear brandsmail genericretail brand vari base drug drug least least least least least least scriptcontract contract term vari base drug drug class
exhibit exampl gross-to-net spread impact discount
mani contract term underwritten brand inflat accord iqvia
sinc brand inflat current expect mid-singl digit actual decreas inflat
creat potenti shortfal gross rebat earn vs guarante client contract list price
increas pharmaceut compani potenti continu moder due high political/publ
scrutini drug price believ could put near-term pbm margin pressur spread
rebat reimburs narrow contract pure pass-through guarante could loss
least rebat compon
page
differ gross vs net price price brand gross net gross net spreadmid gross net spreadlow gross net spreaddiscount avail incl rebat awp
exhibit lack brand price inflat neg impact profit pbm contract underwritten brand
inflat higher
would point recent esrx disclosur exhibit indic compani
